EAErhan Astarci

Erhan Astarci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erhan Astarci has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Carbazole substituted BODIPY dyes: Synthesis, photophysical properties and antitumor activity

    by Ibrahim F. Sengul, Elif Okutan, Hakan Kandemir, Erhan Astarcı, Bünyemin Çoşut


  • An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells

    by Ertan Altayli, Özgür Koru, Önder Öngörü, Tayfun İde, Cengizhan Açikel, Meral Sarper, Mualla Pınar Elçi̇, Rahşan ILIKÇI SAĞKAN, Erhan Astarci, Duran Tok, et al.

    In this study, the in vitro and in vivo effectiveness of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester (CAPE) in combination with bortezomib, a proteasome inhibitor, was explored in multiple myeloma (MM) cells. The cytotoxic effects of CAPE and bortezomib were determined by XTT cell proliferation assay. Apoptosis levels were analyzed with annexin V-fluorescein isothiocyanate, nuclear factor kappa beta (NF-κB) was analyzed with electrophoretic mobility-shift assay, and interleukin (IL)-6 levels were analyzed with enzyme-linked immunosorbent assay to evaluate CAPE's mechanism of action. To investigate the in vivo effectiveness of CAPE and bortezomib, an experimental plasmacytoma model was induced in BALB/c mice. Increasing concentrations of CAPE and bortezomib decreased the proliferation of ARH-77 cells in a dose-dependent manner. With doses of CAPE IC50, a significant increase in apoptosis and a significant decrease in IL-6 levels were detected. The NF-κB DNA- binding activity decreased compared to the basal ARH-77 level. The administration of CAPE alone or in combination with bortezomib increased the rate of survival compared to the control group. We think that our study, which is the first to demonstrate the in vitro and in vivo effectiveness of the.combined use of CAPE and bortezomib, will be a pioneer for future human applications of CAPE in MM.


  • Open Access

    The NF‐κB target genes ICAM‐1 and VCAM‐1 are differentially regulated during spontaneous differentiation of Caco‐2 cells

    by Erhan Astarci, Asli Sade, Ismail Çimen, Berna Savaş, Sreeparna Banerjee

    Intestinal epithelial differentiation entails the formation of highly specialized cells with specific absorptive, secretory, digestive and immune functions. Cell–cell and cell–microenvironment interactions appear to be crucial in determining the outcome of the differentiation process. Using the Caco‐2 cell line, which undergoes spontaneous re‐differentiation when grown past confluency, we observed a loss of VCAM‐1 (vascular cell adhesion molecule 1) mRNA expression, while ICAM‐1 (intercellular cell adhesion molecule 1) mRNA expression was seen to increase over the course of differentiation. Protein kinase Cθ (PKCθ) acted downstream of protein kinase Cα (PKCα) to inactivate inhibitor of κB (IκB) and activate nuclear factor κB (NF‐κB) in undifferentiated cells, and this pathway was inhibited in the differentiated cells. The increase in ICAM‐1 mRNA expression in the differentiated cells was due to increased promoter recruitment of C/EBPβ, which transcriptionally up‐regulated ICAM‐1 mRNA. However, protein expression of ICAM‐1 was found to decrease over the course of differentiation due to degradation in the proteasome and lysosome. Immunohistochemistry using tumor samples from colon cancer patients indicated that non‐transformed matched normal cells (well‐differentiatied) showed no ICAM‐1 expression, but the poorly differentiated tumor cells showed higher expression. Functionally, a decrease in adhesion to human umbilical vein endothelial cells was observed in the differentiated Caco‐2 cells. Thus, regulation of ICAM‐1 and VCAM‐1, although both NF‐κB target genes, appears to be different over the course of epithelial differentiation in Caco‐2 cells.


  • Open Access

    Matrix metalloprotease 16 expression is downregulated by microRNA‐146a in spontaneously differentiating Caco‐2 cells

    by Erhan Astarci, Ayşe E. Erson‐Bensan, Sreeparna Banerjee

    Cellular differentiation in the gut is vital in maintaining the cellular and functional specialization of the epithelial layer. MicroRNAs (miRNAs) have recently emerged as one of the key players in orchestrating the differentiation process in the gut. Using the spontaneously differentiating Caco‐2 cell line, we observed an increased expression of miR‐146a but not miR‐146b in the course of differentiation. Bioinformatic analyses revealed that the membrane type matrix metalloprotease 16 (MMP16, MT3‐MMP) was a predicted target of miR‐146a and a decrease in the mRNA and protein expression of MMP16 was observed in the course of differentiation. Transfection of a luciferase reporter vector containing the 3′UTR of MMP16 showed decreased luciferase activity due to miR‐146a expression. With forced expression of miR‐146a in undifferentiated Caco‐2 cells, a decrease in the mRNA and protein levels of MMP16 and a lower gelatinase activity in a gelatin zymogram were observed. Additionally, forced expression of miR‐146a in HT‐29 colon cancer cells also resulted in decreased expression of MMP16, along with a decrease in the invasion through Matrigel. Taken together, we have shown here that MMP16 is regulated by miR‐146a in spontaneously differentiated Caco‐2 cells. As MMP16 activates the zymogen of MMP2, which is known to degrade extracellular matrix proteins, the regulation of MMP16 by miR‐146a may account, at least in part, for lower motility of well‐differentiated cells.


  • 15‐lipoxygenase‐1 exerts its tumor suppressive role by inhibiting nuclear factor‐kappa B via activation of PPAR gamma

    by I. Cimen, E. Astarci, S. Banerjee

    15‐Lipoxygenase‐1 (15‐LOX‐1) is an enzyme of the inflammatory eicosanoid pathway whose expression is known to be lost in colorectal cancer (CRC). We have previously shown that reintroduction of the gene in CRC cell lines slows proliferation and induces apoptosis (Cimen et al. [2009] Cancer Sci 100: 2283–2291). We have hypothesized that 15‐LOX‐1 may be anti‐tumorigenic by the inhibition of the anti‐apoptotic inflammatory transcription factor nuclear factor kappa B. We show here that ectopic expression of 15‐LOX‐1 gene in HCT‐116 and HT‐29 CRC cell lines inhibited the degradation of inhibitor of kappa B (IκBα), decreased nuclear translocation of p65 and p50, decreased DNA binding in the nucleus and decreased transcriptional activity of Nuclear factor kappa B (NF‐κB). As the 15‐LOX‐1 enzymatic product 13(S)‐HODE is known to be a peroxisome proliferator‐activated receptor gamma (PPARγ) agonist, and NF‐κB can be inhibited by PPARγ, we examined whether activation of PPARγ was necessary for the abrogation of NF‐κB activity. Our data show that the inhibition of both early and late stages of NF‐κB activation could rescued by the PPARγ antagonist GW9662 indicating that the inhibition was most likely mediated via PPARγ. J. Cell. Biochem. 112: 2490–2501, 2011.